In8Bio, Inc. Stock Price, News & Analysis

IN8bio, Inc. (Nasdaq: INAB) successfully closed an underwritten public offering of 5,394,737 shares of its common stock at $1.90 per share, generating approximately $10.25 million in gross proceeds. The offering, managed by H.C. Wainwright & Co., included a 30-day option for the underwriter to purchase an additional 657,894 shares. This transaction was facilitated through a registration statement filed with the SEC, effective August 11, 2022. The funds are intended to support the company's clinical development of gamma-delta T cell therapies.

IN8bio recently announced a preclinical program for iPSC-derived gamma-delta T cells, presenting findings at the ASGCT Annual Meeting. The Phase 1 trial of INB-200 showed five of six patients exceeded expected progression-free survival (PFS), while two surpassed overall survival (OS) benchmarks. INB-100 Phase 1 trial data revealed two of three leukemia patients relapse-free at two years. The company appointed new executives to bolster its management team. Financially, R&D expenses rose to $3.5 million, with a net loss of $7.2 million for Q2 2022, and cash reserves decreased to $25.7 million.

IN8bio announced a public offering of 5,394,737 shares at $1.90 each, expected to close by August 16, 2022. The offering could generate approximately $10.25 million before expenses. H.C. Wainwright & Co. is the sole book-running manager, with an option for additional 657,894 shares. The registration statement was declared effective on August 11, 2022. IN8bio focuses on innovative gamma-delta T cell therapies for tumors, emphasizing its DeltEx platform's capabilities.

IN8bio, Inc. (Nasdaq: INAB) announced promising progress in its Phase 1 trial of INB-100 for high-risk relapsed acute myeloid leukemia (AML) patients. All three patients treated remain alive and disease-free for more than one year post-transplant, with two patients exceeding two years in complete remission. The therapy shows a manageable safety profile, with no severe adverse effects or dose-limiting toxicities reported. The data suggests potential for improved cure rates in AML without significant added risks, with further patient data expected later in 2022.

IN8bio, Inc. (Nasdaq: INAB) announced the issuance of a new European patent covering its Drug Resistant Immunotherapy (DRI) platform, expanding its intellectual property to include NK cells alongside gamma-delta T cells. This patent enhances IN8bio’s position in developing cellular therapies for solid tumors, emphasizing its innovative approach to combat cancer through genetically engineered immune cells. The company is actively advancing its pipeline, including ongoing Phase 1 trials for INB-200 and INB-100, aimed at treating glioblastoma and leukemia, respectively.

IN8bio, Inc. (Nasdaq: INAB) announced the appointment of Kenneth R. LaMontagne, Ph.D., as Senior Vice President of Business Development, aiming to enhance partnership strategies for gamma-delta T cell therapies. Dr. LaMontagne brings over 20 years of experience in cell therapies and oncology, with a history of significant transaction execution in his past roles at Artisan Bio and Bristol Myers Squibb. CEO William Ho emphasized the strategic importance of this leadership addition to increase shareholder value and advance the company's comprehensive pipeline in clinical development.

IN8bio (Nasdaq: INAB) has announced its participation in key conferences this July, focusing on its innovative gamma-delta T cell therapies. The company will present at the Oppenheimer Summit on July 20, with CFO Patrick McCall and CMO Dr. Trishna Goswami available for 1x1 partnering. Additionally, at the 3rd Annual Gamma-Delta T Cell Therapies Summit in Boston (July 26-28), CSO Lawrence Lamb will lead discussions and presentations on maximizing therapeutic outcomes. Lastly, CEO William Ho will deliver a keynote at the GEN Cell & Gene Therapy Summit on July 27.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced that CEO William Ho will present at the Jefferies Global Healthcare Conference on June 8, 2022, from 1:30 to 1:55 p.m. EDT. The presentation will focus on the company's innovative gamma-delta T cell therapies and its DeltEx platform. Additional upcoming presentations include the Biotechnology Innovation Organization International Convention and the Next Generation CAR & T Cell Therapies event. IN8bio is conducting Phase 1 clinical trials for INB-200 and INB-100, targeting glioblastoma and leukemia.

IN8bio, Inc. (Nasdaq: INAB) reported promising results from its Phase 1 trial for INB-200 in glioblastoma multiforme (GBM) patients. Notably, 100% of patients exceeded the median progression-free survival (PFS), with some exceeding overall survival (OS) expectations. One patient remains stable after one year post-enrollment. The safety profile was manageable with no severe adverse events reported. Enrollment for the third cohort has begun, with further updates anticipated later in 2022.